A H Gershlick University Hospital of Leicester UK A H Gershlick University Hospital of Leicester UK AA 2008 Who should we rescue ?

Slides:



Advertisements
Similar presentations
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
Advertisements

Chapter 3 for 12 Lead Training -Precourse-
Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Efficacy and Safety.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
Utilization of Rescue and Facilitated Angioplasty for Primary PCI: Who Should Get Lytic Therapy in 2009? Adnan Kastrati Deutsches Herzzentrum, Technische.
AB London 27/1/2005 Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary.
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty Christopher.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Primary PCI Treatment of choice for Acute MI.
Time Is Myocardium and the Wavefront of Necrosis CM Gibson 2002.
GUSTO I GUSTO I Median Time (hrs) Between Symptom Onset and Treatment GUSTO III GUSTO III InTIME II InTIME II ASSENT.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
ACS and Thrombosis in the Emergency Setting
A modern thrombolysis service is superior to primary angioplasty
Prehospital Fibrinolysis with Double Antiplatelet Therapy in Acute ST-Elevation Myocardial Infarction: The Clarity Ambulance Substudy Prehospital Fibrinolysis.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Role of Percutaneous coronary intervention (PCI) after thrombolytic therapy By Dr. Mohamed Mahros Assistant lecturer of cardiology Benha faculty of medicine.
Primary Angioplasty – The case is not proven: pre-hospital thrombolysis with mandated PCI may be equally effective Primary Angioplasty – The case is not.
Presentation at a Non PCI Facility Requiring Transfer Does NOT Worsen Long-term Prognosis in Patients With STEMI Undergoing Primary Angioplasty. The HORIZONS-AMI.
Management Of AMI Does time matter?? What is the best strategy: PPCI Vs TT.
Advanced Angioplasty 2006 Trial Update 2 Other Trials Alun Harcombe from 1 April: Nottingham University Hospitals NHS Trust NO CONFLICT OF INTEREST TO.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Myocardial Ischaemia National Audit Project Are we replacing good fibrinolytic treatment with poor primary PCI? John Birkhead who has NO CONFLICT OF INTEREST.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San.
Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.
Lysis and Beyond: ESC Guidelines and Reality J N Townend Queen Elizabeth Hospital Birmingham.
The 90 Minute Wall: 60% Rates of TIMI Grade 3 Flow % TIMI 3 Flow.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
Acute Coronary Syndromes SIGN 93. MINAP Mortality after Acute Coronary Syndromes Cumulative: 13.6% Blue 10.6% Green 11.6% Red.
Atypical Presentations Patients older than 75: frequently no chest pain ECG in evolution (nonspecific ECG changes) Diabetic patients: commonly no chest.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
Disclosure Statement of Financial Interest
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Management of ST-Elevation Myocardial Infarction
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
The European Society of Cardiology Presented by Dr. Saman Rasoul
European Heart Association Journal 2007 April
European Society of Cardiology 2003
The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
American College of Cardiology Presented by Dr. Michel R. Le May
What oral antiplatelet therapy would you choose?
Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Ron J.G. Peters,
Maintenance of Long-Term Clinical Benefit with
European Heart Journal Advance Access
16-year follow-up of the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial PG Thranea, SD Kristensena, KKW Olesena, LS Mortensenb, HE Bøtkera, L.
Presentation transcript:

A H Gershlick University Hospital of Leicester UK A H Gershlick University Hospital of Leicester UK AA 2008 Who should we rescue ?

Thrombolysis Tissue Plasminogen activator

patients 53% early reperfusion 52% thrombolysis Thrombolysis studied in pt lives saved / 1000 Thrombolysis studied in pt lives saved / 1000

Acute MI CatchmentsTertiary PCI Catchments Is P-PCI deliverable everywhere

While there is still lysis, there will be lytic failure Failure ? : “TIMI 3” In the real world ? ST segment 60/ 90 min Failure ? : “TIMI 3” In the real world ? ST segment 60/ 90 min X Normal Flow 60% 40%

Who should we Rescue ?  - ? markers of lytic failure o Pain - insensitive - MERLIN 43% R-PCI (ECG) pain free - TAMI -5 – clinical variables not predictive o Biomarkers –sensitivity 92% specificity 56% Stewart JACC

Schroder R et al. JACC 1995;26:

Peak CK values in relation to the sum of ST-segment resolution (100%, 70% or 30% cut-offs) 3 hours following start of thrombolytic therapy Schroder R et al. JACC 1995;26:

The Data :

2004

Cumulative Event-free Survival following R-PCI versus Conservative Therapy REACT MERLIN Gershlick AH et al NEJM 2005;353: Sutton AGC et al JACC 2004;44:

Differing Methodology: REACT versus MERLIN Centres 35 5 ST Resolution 50% at 90mins 50% at 60 mins 10% had TIMI III at angios 40% TIMI III at angio SK 58% 96% Stents 69% 50% GP IIb-IIIa use 43% 3% PCI arm- PCI mandated not mandated completed in 96.5% completed in 66% PCI within 30 days 2% of conservative group 20% conservative group Recruitment 3.3 patients /centre/ year 30.7 patients/centre/year Heart failure “NYHA III or IV” Diuretics

Outcome MERLIN versus 1 year Outcome MERLIN versus 1 year

12 month & Long term 12 month & Long term REACT Trial

Mortality – to a median 4 ½ years

death death/reAMI

RESCUE PCI – HOW DO THE OUTCOMES FROM ‘REAL-WORLD’ PATIENTS COMPARE TO THE PUBLISHED TRIALS ? 185 Consecutive Rescue PCI patients April August glenfield Clinical follow-up via PCI database, case-note review and ONS, at a mean of 4.5months Mean (SD) delay from symptom onset to PCI =501 (229) minutes [8.35 hours], range min Kelly DJ, Siddiqui N, Holt M, Gershlick AH-Submitted to BCS

2007 R-PCI Registry vs REACT Trial * Mean 4.5month Follow-up **6/12 Follow-up % 2007 Registry*REACT Trial** Death Re-AMI CVA Heart Failure MACE

Local vs Transfer Patients p=0.322 p=0.42 Mean Delay 438minMean Delay 525min % Local PCI Centre Patients Transferred Patients Mortality MACE 7.3 hrs 8.75 hrs Mean Delay S-B

When ? : Timing issues

GRACE REGISTRY- Relationship between door-to-needle time and 6-month mortality among1786 patients undergoing fibrinolytic therapy for AMI Nallamothu B et al Heart 2007;93:1552-5

Time (hrs) Lytic to R- PCI Symptom to R-PCI 4.6 hours6.9 hours

REACT delay after symptom onset 1

Mortality versus Tertile of Delay (Symptom onset to R-PCI) *Mean Delay from Symptom Onset to R-PCI (all patients) p= All-cause Mortality (%) Shortest 290 min* Mid tertile 485 min Longest 694 min Registry

Rescue PCI : o All failed lytic (25%-30%) failure to resolve max St  to > 50% at 90 mins o As soon as possible ( Sympt - balloon < 3 hrs) Who not to “rescue”

1082 PCI 1084 OMT 3–28 days post AMI

“Mm… shall I give repeat thrombolysis ?” REACT – Bleeding Outcomes REACT – Bleeding Outcomes % % MAJOR ( > 3g/dl) MAJOR ( > 3g/dl) Lysis C RPCI Lysis C RPCI OVERT Bld No OVERT Bld 22/27 (82%) sheath 22/27 (82%) sheath 3 HPericard 1 Death 3 HPericard 1 Death 1 H thorax 1 Death 1 H thorax 1 Death

What can Rescue –PCI do for you ?

Pre-Hospital 4.30 am 6 am 6.45 Pre-Hospital 4.30 am 6 am 6.45

RESCUE–PCI should be mandated & be part of AMI protocols Repeat lytic may be dangerous RESCUE–PCI should be mandated & be part of AMI protocols Repeat lytic may be dangerous

Conservative Rescue (n=154) (n=153) Death Re-AMI Stroke Heart failure REACT 30 day MERLIN

Time hrs Time hrs L 1 – L (3.2 hrs) L 1 -RPCI 274 (4.6 hrs) 84 mins 1.4 hrs 1.4 hrs 84 mins 1.4 hrs 1.4 hrs R Pain D Door to 1 st lytic 27 mins (0-3736) Pain to 1 st lytic 140 mins ( ) 113 Pain to 2 nd lytic 330 mins ( ) 2 nd lytic Pain to R-PCI 414 mins ( ) MEDIAN TIMES

REACT delay after symptom onset 2

REACT delay after randomisation

R-PCI trials

*1 st anterior ‘failed reperfusion’ **1 st anterior ‘occluded LAD’ Adapted from Kunadian B, et al. J Invasive Cardiol 2007 Sep;19(9):359-68

MERLIN: 30-day Mortality according to ST-segment resolution 6 hours after initiation of fibrinolytic therapy Sutton et al JACC 2004;44:287-96

Timing of AMI Rx

Absolute Reduction in 35-day Mortality versus Delay from Symptom Onset to Randomization Among Patients with ST-segment elevation or LBBB Fibrinolytic Therapy Trialists’ Collaborative Group. Lanct 1994;343:

Use of reperfusion therapy in 376,753 patients from NRMI-4 with STEMI or LBBB within 12 hours of symptom onset Curtis JP et al JACC 2006;47:

GRACE REGISTRY- Relationship between door-to-needle time and 6-month mortality among 2173 patients undergoing Primary PCI for AMI Nallamothu B et al Heart 2007;93:1552-5

Wiviott SD et al JACC 2004;44:783-9) Mortality versus NRMI-4 Risk Index following AMI

Curtis JP et al JACC 2006;47:

Thrombolysis Primary PCI

Denmark Czech Republic

Management of acute myocardial infarction in patients presenting with ST-segment elevation Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology Frans van der Werf EHJ 2003 ‘Rescue PCI’ is defined as PCI performed on a coronary artery which remains occluded despite fibrinolytic therapy. Limited experience from two randomised trials suggest a trend towards clinical benefit…. Class IIa Level of evidence B Weight of evidence in favour of usefulness Data from limited number of randomised trials involving small numbers of patients or from careful analysis of registry/observational Management of acute myocardial infarction in patients presenting with ST-segment elevation Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology Frans van der Werf EHJ 2003 ‘Rescue PCI’ is defined as PCI performed on a coronary artery which remains occluded despite fibrinolytic therapy. Limited experience from two randomised trials suggest a trend towards clinical benefit…. Class IIa Level of evidence B Weight of evidence in favour of usefulness Data from limited number of randomised trials involving small numbers of patients or from careful analysis of registry/observational

Intuitive to perform PCI But Rescue PCI is not Primary  Why did lysis fail ?  clot burden, disrupted vessel,  PCI in the setting lytic administration (activation platelets, release thrombin)  Time delay  Patients sicker Intuitive to perform PCI But Rescue PCI is not Primary  Why did lysis fail ?  clot burden, disrupted vessel,  PCI in the setting lytic administration (activation platelets, release thrombin)  Time delay  Patients sicker

Late 1990s

RESCUE I Trial Results Randomised Evaluation of Salvage Angioplasty with Combined Utilization of Endpoints Ellis et al. Circulation 90(5) % DeathSevere heart failure Death or severe heart failure Angioplasty 78 Conservative 73 p=0.18 p=0.11 p=0.05 Background

2004

REACT ( RE scue A ngioplasty v C onservative treatment or repeat T hrombolysis ) ECG 90 min post (any incl SK) thrombolytic ST < 50 % resolution (with or without pain) CONSENT & RANDOMISE Conservative 2 nd thrombolytic Coronary Angio 24 iv heparin Accelerated tPA or +/- PCI Reteplase primary end point: 6/12 ~death/re-infarction/severe HF/CVA REACT ( RE scue A ngioplasty v C onservative treatment or repeat T hrombolysis ) ECG 90 min post (any incl SK) thrombolytic ST < 50 % resolution (with or without pain) CONSENT & RANDOMISE Conservative 2 nd thrombolytic Coronary Angio 24 iv heparin Accelerated tPA or +/- PCI Reteplase primary end point: 6/12 ~death/re-infarction/severe HF/CVA 2000

Inclusion Criteria uAcute Myocardial Infarction uAspirin + Thrombolytic within 6 hours uAge 21yrs - 85 yrs uAbility to perform intervention within 12hrs of onset symptoms uFailed reperfusion (ECG < 50% resolved) uAcute Myocardial Infarction uAspirin + Thrombolytic within 6 hours uAge 21yrs - 85 yrs uAbility to perform intervention within 12hrs of onset symptoms uFailed reperfusion (ECG < 50% resolved)

Exclusion Criteria Safety pre-requisites pre randomisation (thrombolytic) Safety pre-requisites pre randomisation (thrombolytic) a. Hb, Hct & platelet count b. Weight (< 65 kg) c. Age (> 85 y) d. Any evidence bleeding e. Hypertension during admission (after administration first lytic; age ) f. CGS {g. LMW heparin} {g. LMW heparin} Safety pre-requisites pre randomisation (thrombolytic) Safety pre-requisites pre randomisation (thrombolytic) a. Hb, Hct & platelet count b. Weight (< 65 kg) c. Age (> 85 y) d. Any evidence bleeding e. Hypertension during admission (after administration first lytic; age ) f. CGS {g. LMW heparin} {g. LMW heparin}

Demographics slide 1 n=427 Group A (n=142) R -LYSIS Group B (n=141) CONSERVATIVE Group C (n=144) R-PCI Male80.3%78.7%78.5%79.2% Age61.3 (10.3) y61.0 (10.7) y61.1 (11.9) y61.1 (11.0) y H/o angina 22.5%20.6%22.2%21.8% H/o AMI n= %12.1%9.8% (p= 0.1) 12.7% H/o PCI4.2%2.8%4.2%3.7% H/o CABG4.9%2.8%4.9%4.2% H/o Diabetes16.2%11.3%14.6%14.1% H/o HT42.3%37.6%32.6%37.5% SmokingCurr 49.6% Prev 29.1% Curr 46.1% Prev 29.8% Curr 47.2% Prev 27.8% Curr 47.7% Prev 28.9% RESULT S All patients

Demographics n=427* AnteriorInferior Post/Lateral Totals First lytic First Lytic rPA (26%) SK ( 60% ) TNK73010 (2%) tPA (12%) Total Regions 182(43%) (55%)8(2%) 426 (*1 unknown)

6 month data REACT Trial

Primary composite endpoint: (death and non-fatal re-AMI, CVA, Severe HF) Primary composite endpoint: (death and non-fatal re-AMI, CVA, Severe HF) RESULTS No. of subjects with a component of the Composite Primary End any time within 6 months N=142 R-LYSIS N=142 R-LYSIS N=141 Conservative N=141 Conservative N=144 R-PCI N=144 R-PCI 44 ( 31.0%) 44 ( 31.0%) 42 (29.8%) 42 (29.8%) 22 (15.3%) 22 (15.3%) R-PCI v Repeat lytic p< R-PCI v Conservative p< 0.01 Repeat lytic v Conservative NS

R-PCI R-lysis C

Group Group (Death, AMI, CVA or Severe Heart Failure) Comparative Group vs Reference Group Favours Comparative Favours Reference Hazard Ratio R-PCI vs Conservative Repeat Lysis vs Conservative R-PCI vs Repeat Lysis HR= % CI 0.28 to 0.79 HR= % CI 0.27 to 0.75 HR= % 0.68 to 1.59 n=285 n=286 n=283 COMPOSITE END POINT Hazard Ratios and 95% CI at 6 Months p=0.80 p=0.002 p=0.004

R-PCI leads to a consistently lower event rate within each age group For all patients, increasing age had an adverse effect upon 1 o endpoint (HR=1.05, 95% CI (p<0.0001) Relative incremental risk of an event increased by 5% per year of age Impact of age on 6 month 1 o endpoint (ITT analysis) ARR: 14-17%7-10%22-30%29-34% Absolute risk reduction of R-PCI appears greater in patients >70 Characteristics similar across age ranges within and between groups

R-PCIRpt LysisConser 91% F-up

months 6-12 months months 6-12 months Re-vasc

0.08 R-PCIRpt LysisConser

Secondary End Point Hazard Ratio R-PCI vs Repeat Lysis vs Conservative R-PCI vs Repeat Lysis Hazard Ratios and 95% CI of Revascularisation at 6 Months Comparative Group vs Reference Group Favours Comparative Favours Reference Group Group HR= % CI 0.34 to 1.09 HR= % CI 0.30 to 0.93 HR= % 0.70 to 1.90 n=285 n=286 n=283 p=0.57 p=0.03 p= 0.10

R-PCIRpt LysisConser NS

Mortality REACT Trial

0.13

Hazard Ratios and 95% CI of Mortality at 6 Months R-PCI vs Conservative Repeat Lysis vs Conservative R-PCI vs Repeat Lysis Favours Comparative Favours Reference Group Group Hazard Ratio HR= % CI 0.21 to 1.06 HR= % CI 0.21 to 1.06 HR= % 0.52 to 1.92 n=285 n=286 n=283 Comparative Group vs Reference Group p= 0.07

Longer term mortality ONS Patient specific NHS No.

Mortality for 416 /427 patients at median 4.4 years R PCI 19 % C 28 % R lysis 24 %

REACT trial Longer term outcome Events and difference in outcome happens early Benefit is maintained out to 12 months Late (4.4) year data indicates longer term mortality benefit In general R-PCI Where lysis is still a reperfusion strategy Failed lysis (< 50% ST segment 90 mins) should be treated with Rescue – PCI R-PCI should be part mandated reperfusion protocols timing issues are unresolved ASAP (within 3 hours of ECG  ) REACT trial Longer term outcome Events and difference in outcome happens early Benefit is maintained out to 12 months Late (4.4) year data indicates longer term mortality benefit In general R-PCI Where lysis is still a reperfusion strategy Failed lysis (< 50% ST segment 90 mins) should be treated with Rescue – PCI R-PCI should be part mandated reperfusion protocols timing issues are unresolved ASAP (within 3 hours of ECG  )

Numbers at risk R-PCI Repeated thrombolysis Conservative

REACT delay after symptom onset 1

REACT delay after symptom onset 2

REACT delay after randomisation

MERLIN REACT Time sypmt to hospital 10 6 Pain to lysis 180 mins 140 mins ECG 6o mins 90 mins SK 96% 60% Stents 50.3% 68.5% GP IIbIIIa 3.3% 43.4% Pain to cath lab 320 mins 420 mins Local v National Definitions (HF) MERLIN REACT Time sypmt to hospital 10 6 Pain to lysis 180 mins 140 mins ECG 6o mins 90 mins SK 96% 60% Stents 50.3% 68.5% GP IIbIIIa 3.3% 43.4% Pain to cath lab 320 mins 420 mins Local v National Definitions (HF)

Conservative Rescue p value (n=154) (n=153) Death Re-AMI Stroke Heart failure Re-vasculascularisation < 0.01 COMPOSITE MERLIN 30 day JACC 2004,4, REACT 30 day

Thrombolysis :(+ APT) tested in pts  Saves lives per thousand  Easy to administer  It is where the patients attend  No extra training  Starting to understand its limitations  Using pharmacology on way to cath lab not appropriate (ASSENT 4 FINESS) Thrombolysis :(+ APT) tested in pts  Saves lives per thousand  Easy to administer  It is where the patients attend  No extra training  Starting to understand its limitations  Using pharmacology on way to cath lab not appropriate (ASSENT 4 FINESS) Achieving recommended time lines for P-PCI may be difficult

Schroder R et al. JACC 1995;26:

Admission Lysis 90 min repeat ECG Admission Lysis 90 min repeat ECG Giving lytic and going to bed is not enough !!! Primary Strategy